Life expectancy in HIV: Better, but not good enough

BMJ (Online)

Volumn 343, Issue 7829, 2011, Pages

  Losina, Elena ^a   Freedberg, Kenneth A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; EDITORIAL; HEALTH BEHAVIOR; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCREENING TEST; SEX DIFFERENCE; UNITED KINGDOM; DELAYED DIAGNOSIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NOTE;

ANTI-HIV AGENTS; DELAYED DIAGNOSIS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIFE EXPECTANCY; MALE;

EID: 84859000689     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6015     Document Type: Editorial

References (12)

1. UNAIDS. UNAIDS report on the global AIDS epidemic. 2010. www.unaids.org/globalreport/global-report.htm.
2. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-9.
3. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011;343:d6016.
4. Golin CE, Liu HH, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65. (Pubitemid 35286241)
5. UNAIDS. UNGASS country progress report United Kingdom. 2010. www.unaids.org/en/dataanalysis/monitoringcountryprogress/ 2010progressreportssubmittedbycountries/unitedkingdom-2010-country-progress- report-en.pdf.
6. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009;49:1570-8.
7. Postma MJ, Beck EJ, Hankins CA, Mandalia S, Jager JC, de Jong-van den Berg LTW, et al. Cost effectiveness of expanded antenatal HIV testing in London. AIDS 2000;14:2383-9.
8. Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-63.
9. Heslin KC, Andersen RM, Ettner SL, Cunningham WE. Racial and ethnic disparities in access to physicians with HIV-related expertise. J Gen Intern Med 2005;20:283-9.
10. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals - estimating potentially avoidable deaths. JAMA 2000;283:1159-66. (Pubitemid 30126604)
11. Hellinger F. Practice makes perfect - a volume-outcome study of hospital patients with HIV disease. J AIDS 2008;47:226-33. (Pubitemid 351172191)
12. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006;82:56-63.